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Three-dimensional tumor cell growth stimulates
autophagic flux and recapitulates chemotherapy
resistance
Corinna Bingel1,6, Emily Koeneke1,2,6, Johannes Ridinger1,2,6, Annika Bittmann1,2, Martin Sill3, Heike Peterziel1,2, Jagoda K Wrobel1,2,
Inga Rettig1,7, Till Milde1,2,4, Uta Fernekorn5, Frank Weise5, Andreas Schober5, Olaf Witt1,2 and Ina Oehme*,1,2
Current preclinical models in tumor biology are limited in their ability to recapitulate relevant (patho-) physiological processes,
including autophagy. Three-dimensional (3D) growth cultures have frequently been proposed to overcome the lack of correlation
between two-dimensional (2D) monolayer cell cultures and human tumors in preclinical drug testing. Besides 3D growth, it is also
advantageous to simulate shear stress, compound flux and removal of metabolites, e.g., via bioreactor systems, through which
culture medium is constantly pumped at a flow rate reflecting physiological conditions. Here we show that both static 3D growth
and 3D growth within a bioreactor system modulate key hallmarks of cancer cells, including proliferation and cell death as well as
macroautophagy, a recycling pathway often activated by highly proliferative tumors to cope with metabolic stress. The autophagy-
related gene expression profiles of 2D-grown cells are substantially different from those of 3D-grown cells and tumor tissue.
Autophagy-controlling transcription factors, such as TFEB and FOXO3, are upregulated in tumors, and 3D-grown cells have
increased expression compared with cells grown in 2D conditions. Three-dimensional cultures depleted of the autophagy
mediators BECN1, ATG5 or ATG7 or the transcription factor FOXO3, are more sensitive to cytotoxic treatment. Accordingly,
combining cytotoxic treatment with compounds affecting late autophagic flux, such as chloroquine, renders the 3D-grown cells
more susceptible to therapy. Altogether, 3D cultures are a valuable tool to study drug response of tumor cells, as these models
more closely mimic tumor (patho-)physiology, including the upregulation of tumor relevant pathways, such as autophagy.
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The success rates for investigational cancer drugs in clinical
development are poor. The clinical approval rate of com-
pounds for the treatment of solid tumors is 10% or less.1,2
Improving basic research models is critical for achieving
clinical success. Conventionally, preclinical assessment of
chemotherapeutic effectiveness starts in two-dimensional
(2D) cultures, where cell-cell contacts, cell shape andmorpho-
logy significantly differ from tumor cells in a physiological
setting. All of these features strongly influence cellular growth,
behavior and metabolism.3 Three-dimensional (3D) growth
cultures have been introduced for preclinical drug screening to
improve the correlation between cell cultures and tumors.4
Three-dimensional cell growth is associated with a spherical
shape, affecting gene and protein expression, survival,
proliferation, differentiation, and metabolism.5,6 Furthermore,
3D-grown tumor cells display enhanced resistance to radio-
and chemotherapy.7,8 Additional important characteristics
of the physiological setting include the flow of extracellular
fluids, leading to shear stress, compound flux and removal
of metabolites. Small 3D bioreactor systems mimic these
properties by pumping medium at a physiologically represen-
tative flow rate.6,9
Neuroblastoma, a common pediatric tumor of the sympa-
thetic nervous system, is characterized by a wide range
of clinical courses.10 Despite intensification of treatment,
high-risk neuroblastoma patients have a very poor prognosis
due to chemotherapy resistance.10,11 We and others have
previously reported that macroautophagy (hereafter auto-
phagy) supports chemotherapy resistance in neuroblastoma
cells.12,13 Thus, neuroblastoma is a good model to investigate
autophagy-related drug resistance.
Autophagy is an evolutionarily conserved process, involving
sequestration of cytoplasmic components within a double-
membrane structure (autophagosome) and subsequent deliv-
ery to lysosomes for degradation.14 Metabolic or therapeutic
stress, e.g. DNA-damaging drugs, may induce autophagy,15
which is regulated by autophagy-related (ATG) genes.14
Whereas autophagy plays a tumor-suppressive role in
early stages of tumorigenesis, it can support growth at
later stages, allowing tumor cells to survive with limited
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oxygen and nutrients, as well as under cytotoxic treatment
conditions.16
Histone deacetylase (HDAC) inhibitors interfere with key
tumor-relevant pathways, including proliferation, apoptosis,
differentiation and autophagy in several cancer entities in vitro
and in vivo.17–19 The human HDAC family comprises four
classes: class I, II, subdivided into classes IIa and IIb, III and
IV.20–22 Class IIb family members (HDACs 6 and 10) are linked
to cellular stress, protein degradation and autophagy.12,23–26
We have previously identified HDAC10 as a mediator of
autophagic flux in neuroblastoma and inhibition as well as
depletion of HDAC10 sensitized monolayer neuroblastoma
cells to cytotoxic drugs.12
It remains unclear how different cell culture settings
influence autophagy, particularly in the context of drug
development and therapy resistance. Here we show that
3D culture models are a suitable tool for screening drug
responses of tumors. Additionally, these models are useful for
mechanistically studying cancer-relevant processes, as they
more accurately resemble transcriptional profiles of tumors
and recapitulate the regulation of physiologically relevant
pathways, including autophagy. Our data suggest that 3D
tumor models are advantageous when studying autophagy-
targeting treatment and resistance mechanisms.
Results
Expression profiles fromMYCN-amplified neuroblastoma
cell lines and tissues are highly discrepant. Tumor cells
tend to lose many hallmarks of cancer over time when
cultured in vitro under standard conditions. We explored
differences between cultured tumor cells and primary tumor
tissues by comparing the gene expression profiles of MYCN
amplified neuroblastoma cell lines with tissue samples from
a publically available data set (Mixed Neuroblastoma –
Versteeg; R2 database). A principal component analysis
(PCA) performed with all genes revealed two distinct clusters
(Figure 1a, Supplementary Figure S1a), indicating that the
gene expression profile after two-dimensional (2D) growth
shifts away from tumor tissue. We hypothesized that three-
dimensional (3D) growth would better recapitulate neuro-
blastoma physiology. Thus, we seeded neuroblastoma cells
in a collagen type I-coated, ridged scaffold model, which
yielded reproducible one-size 3D structures. The polymeric
scaffolds contain 187 microcavities per chip, promoting 3D
growth of multicellular spheroids approximately 200 μm in
diameter (Figure 1b). Corroborating previous findings,27 the
collagen substratum in our system was a suitable extra-
cellular matrix protein, affecting neither population doubling
time nor response to cytotoxic treatment (Supplementary
Table 1). To account for additional physiological factors, we
also inserted the chips into a bioreactor system,9 which
simulates the flow of extracellular fluids (Supplementary
Figures S1b and c).
A typical histomorphological feature of undifferentiated
and aggressive neuroblastoma tumors is its small round
blue cell phenotype (Supplementary Figure S1d), which is
lost upon growth under classical 2D culture conditions.
Two-dimensionally grown cells exhibit flat morphology with
much larger nuclei and fewer cell–cell contacts. In contrast,
3D-grown cells more closely resembled small round blue
cells, characteristic for undifferentiated neuroblastoma tissue
(Figure 1c, Supplementary Figure S1e). Solid tumors are also
metabolically heterogeneous, with areas of maximal growth,
slow-growing starved regions or even necrotic parts.28 Similar
structures are observable within multicellular spheroid 3D
models.29 We investigated whether growing neuroblastoma
cells in the 3D-chip model affected overall cell proliferation and
death rate. Three-dimensionally grown cells exhibited an
increased population doubling time, but still grew exponen-
tially, with slightly decreased overall viability (Supplementary
Table 2). To investigate whether 3D growth affects gene
transcription, we analyzed the gene expression patterns of
BE(2)-C cells grown in 2D, 3D and bioreactor-3D cultures
and compared them to tumor tissue samples from three
different neuroblastoma patients (German Neuroblastoma
Trial cohort30) resembling the characteristics of BE(2)-C cells
(stage 4, amplified MYCN, undifferentiated and 1p deletion).
A PCA revealed that 3D-cultured (static and bioreactor)
neuroblastoma transcriptomes were closer to the neuroblas-
toma tissue profile than the 2D samples (Figure 1d, Supple-
mentary Figure S1f). These results support our hypothesis that
3D growth of cells not only resembles more phenotypic
histology, but also reduces the discrepancy between transcrip-
tional programs in cultured cells and primary tumor material.
Resistance to cytotoxic treatment is enhanced in 3D-
grown neuroblastoma cells. To compare drug response,
we treated 2D- and 3D-grown neuroblastoma cells with the
cytotoxic compounds doxorubicin and vincristine. Three-
dimensional growth strongly hampered the drug-induced
reduction in BE(2)-C cell number compared to 2D growth,
with the IC50 values for doxorubicin and vincristine increas-
ing approximately 7- and 5-fold, respectively (Figures 2a
and b). IMR-32 cells were similarly affected (Supplementary
Figures S2a and b). Neuroblastoma cells grown three-
dimensionally in the bioreactor system were completely
resistant to vincristine (Figure 2c). To examine long-term
effects of drug treatment, we treated 2D- and 3D-cultured BE
(2)-C as well as IMR-32 cells for six days with doxorubicin
and confirmed prolonged resistance in tumor cells cultured
under 3D conditions (Figure 2d). Using the 3D-BE(2)-C
model we tested other clinically-relevant drugs, such as
cisplatin, etoposide and the MET/ALK-inhibitor crizotinib. In
all cases, 3D-cultured cells exhibited a weaker response than
2D-grown cells (Figure 2e). Moreover, six out of a panel of
seven neuroblastoma cell lines had more cells survive
doxorubicin treatment under 3D compared with 2D condi-
tions (Figure 2f). Only NB-1 cells were highly sensitive to
doxorubicin, irrespective of culture conditions. Both MYCN
amplified and MYCN-depleted (shMYCN) IMR5/75 cells
respond less to doxorubicin when cultured in 3D. However,
the difference in drug sensitivity between both conditions was
greater among cells expressing MYCN (2-fold) compared to
MYCN-depleted cells (1.4-fold), suggesting MYCN involve-
ment in mediating resistance. Our findings support the notion
that the lower sensitivity to cytotoxic drugs observed in 3D
cultures more accurately recapitulates chemotherapy resis-
tance than 2D-grown cells and that more representative
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culture conditions could avoid a misleading prediction of drug
sensitivity.
Drug resistance of three-dimensionally grown tumor
cells translates into a suppressed apoptotic response.
As 3D growth yields more treatment-surviving neuroblastoma
cells, we investigated whether programmed cell death was
affected. The number of dead cells (BE(2)-C, IMR-32) in the
subG1-area of the cell cycle profile following doxorubicin or
vincristine treatment clearly differed between 2D and 3D
conditions (Figure 3a). Correspondingly, significantly reduced
activation of effector caspases in response to drug treatment
under 3D culture conditions was observed in both cell lines
(Figure 3b). The difference in caspase activity in 3D versus
2D-grown cells was also reflected by different levels of PARP
cleavage, exemplarily shown for IMR-32 cells (Figure 3c).
Following treatment, the ratio of cleaved to full-length PARP
increased to a significantly greater extent in 2D-grown
compared with 3D-grown cells (8-fold versus 2-fold and 10-
fold versus 5-fold) for doxorubicin and vincristine, respectively
Figure 1 Three-dimensional cell culture models recapitulate typical features of neuroblastoma tumors. (a) Principal component analysis (PCA) of transcriptomes, using gene
expression profiles from 15 MYCN amplified neuroblastoma cell lines (red) and 16 MYCN amplified neuroblastoma tissue samples (green) via the web-based R2 microarray
database (http://r2.amc.nl) and the data set of mixed neuroblastoma cell lines/tissues (‘Versteeg’). The first two principal components, PC1 and PC2, are shown. (b) BE(2)-C cells
grown as monolayers under normal 2D conditions and in 3D culture on collagen-coated polymeric chips with multiple microcavities. Upper left: monolayer, scale bar: 200 μm.
Upper right: Spheroidal 3D-cultured cell cluster freed from its chip, scale bar: 200 μm. Middle panel: 3D culture on chip. Microcavities filled with cells are shown with lower (scale
bar: 500 μm) and higher (scale bar: 200 μm) magnification. Lower panel: highest magnification (scale bar: 100 μm). (c) Representative images of HE (upper panel) and nuclear
staining (lower panel) of BE(2)-C cells grown under 2D (left) or 3D conditions (middle), and neuroblastoma tissue (right). Cells grown for 72 h under 3D conditions were freed from
the polymeric chip for staining. Note that 3D culture leads to a small round blue cell morphology whereas 2D cultures are settled on a flat surface and develop a more ganglionic
phenotype. In addition, under 3D culture conditions, the nuclei are reduced in size. (d) Principal component analysis (PCA) of transcriptomes from 2D (open), 3D-static (3D;
black), 3D bioreactor (3D-BR; blue) 6 d cultures of BE(2)-C cells and three neuroblastoma patient samples (tissue; magenta). The first two principal components PC1 and PC2 are
shown. Note that PC1 separates the transcriptomes into two clusters: Cluster one, in the negative range of the x axis includes neuroblastoma tissue samples and both kinds of 3D-
cultured cells and a separate cluster (positive range) that contains transcriptomes of the 2D-cultured cells
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Figure 2 Three-dimensional cell growth affects drug responsiveness of neuroblastoma cells. BE(2)-C cells grown in monolayer (2D) or in 3D were treated 24 h post-seeding
with doxorubicin (a) or vincristine (b) in various concentrations for 48 h. IC50 values were calculated with GraphPad Prism (San Diego, CA, USA) (function: log(inhibitor) versus
normalized response; variable slope). (c) One day after seeding, chips containing 3D-cultured BE(2)-C cells were transferred into the bioreactor system (3D-BR) and medium or
medium containing vincristine (10 ng/ml) was pumped through the system for 48 h. (d) One day after seeding, 2D- and 3D-cultured BE(2)-C or IMR-32 cells were treated for 6 d
with doxorubicin, where indicated. Doxorubicin concentrations: BE(2)-C: 0.5 μg/ml and IMR-32: 0.01 μg/ml. (e) BE(2)-C cells grown in 2D or 3D were treated 24 h post-seeding
with doxorubicin (0.5 μg/ml), vincristine (0.01 μg/ml), cisplatin (15 μg/ml), etoposide (7.5 μg/ml) or crizotinib (0.8 μM). (f) A panel of neuroblastoma cell lines (BE(2)-C, SK-N-BE,
Kelly, IMR-32, tetracycline-inducible shMYCN IMR5/75 (on/off) and NB1) grown in monolayer (2D) or in 3D was treated 24 h post-seeding with doxorubicin for 48 h. Doxorubicin
concentrations: BE(2)-C: 0.5 μg/ml; SK-N-BE: 0.1 μg/ml, Kelly: 0.05 μg/ml, IMR-32: 0.01 μg/ml, IMR5/75: 0.01 μg/ml, NB1: 0.5 μg/ml. Inlay: Western blot displaying MYCN
expression with (+) or without (− ) doxycycline treatment of inducible shMYCN IMR5/75 cells. (a–f) Number of viable cells was assessed by automated cell counting and trypan
blue exclusion and was normalized to untreated control of each condition. Significant differences between groups were tested using an unpaired, two-tailed t-test. n.s., not
significant; * Po0.05; **Po0.01; ***Po0.001
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(Figure 3d). In summary, our data suggest a decreased
apoptotic response in 3D-grown tumor cells.
Three-dimensional growth affects expression of
autophagy-related genes in neuroblastoma cells. Growth
of tumor cells under spheroidal 3D conditions has been
described to affect drug resistance via cellular pathways
including proliferation, hypoxia and autophagy.31–33 As we
have previously shown the importance of the autophagic
degradation pathway in neuroblastoma cell cultures, we
focused on genes associated with the Gene Ontology (GO)
term ‘autophagy’ (GO:006914) and used the globaltest
R package34 to check for differential regulation between 2D
and 3D cultures. Differentially regulated genes were ranked
according to the component P-value (Supplementary Table
3), and the ten genes with the lowest P-values (TOP10) were
Figure 3 Three-dimensional cell growth impairs apoptosis in neuroblastoma cells. (a) BE(2)-C and IMR-32 cells were grown under 2D- and 3D conditions for 96 h. After 24 h,
doxorubicin or vincristine was added to the media, and 72 h later, the cells and supernatants were collected for the detection of cell death by propidium iodide (PI) staining of
ethanol-fixed cells. Representative histograms for solvent control and doxorubicin-treated IMR-32 cells are shown on the right. (b) One day after seeding, 2D- and 3D-cultured BE
(2)-C and IMR-32 cells were treated for another 48 h with doxorubicin or vincristine, where indicated. Caspase-3 (DEVDase) activity was measured using a fluorometric assay
with activity (slope/min) measured relative to untreated 2D cells. (c) Western blot analysis of PARP cleavage in 2D- and 3D-grown IMR-32 cells 48 h after treatment with
doxorubicin or vincristine where indicated. Cells were cultured for 72 h in total. β-Actin served as a loading control. Numbers indicate the ratio of cleaved to full-length PARP. f.l.,
full-length. (d) Quantification of three biological replicates of the detection of PARP cleavage in 2D- and 3D-grown IMR-32 cells 48 h after treatment with doxorubicin or vincristine
where indicated. Cells were cultured for 72 h in total. (a, b and d) Bars represent mean values of at least three independent experiments, error bars represent S.E.M. Significant
differences between groups were tested using an unpaired, two-tailed t-test. *Po0.05, ***Po0.001. (a–d) Treatment of BE(2)-C: 0.5 μg/ml doxorubicin or 10 ng/ml vincristine.
Treatment of IMR-32: 0.01 μg/ml doxorubicin or 3 ng/ml vincristine
3D models mimic pathophysiological autophagic ﬂux
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verified using semi-quantitative real-time PCR (Table 1). We
additionally included HDAC10 in the validation assays as this
HDAC is also involved in the regulation of autophagic flux in
neuroblastoma cells12 and is closely related to the TOP10 hit
HDAC6. Nine of the TOP10 genes showed differences on
RNA level concordant with the results of the gene expression
analysis. Additionally, we re-evaluated gene expression data
from the MYCN amplified neuroblastoma cell lines and
tumors contained in the ‘Mixed Neuroblastoma’ data set
(Versteeg; R2 database), performing a PCA using all genes
associated with the GO term ‘macroautophagy’. Tissue
samples and cell lines were clearly separated by the PCA
(Figure 4a, Supplementary Figure S3a). Using the same data
set, we performed a clustering analysis with the hit list of
genes obtained from our own microarray analysis. It revealed
an almost complete separation of cell lines from tumor
samples (Figure 4b). A clustering analysis of our own
microarray data using autophagy genes with a P-value less
than or equal to 0.005 revealed two main clusters: 2D versus
3D/tumor tissue (Figure 4c). Of the nine PCR-validated
genes, eight were significantly upregulated in tumor samples
compared to 2D-cultured cell lines not only in our own
microarray data, but also in the publically available R2 data
set (Table 1,Figure 4d). A direct comparison of the TOP10
(plus HDAC10) gene expression among 2D- and 3D-grown
cells with tumor tissue samples using our SDHA-normalized
real-time PCR data as well as the SDHA-normalized
Versteeg microarray data revealed that the gene expression
of 3D-grown cells approaches that of tissue material
(Figure 4e). To determine whether protein levels reflect our
RNA expression profiles, we performed western blot ana-
lyses of ULK1, HDAC6, MAP1LC3A, ATG16L2 and HDAC10.
Additional validation experiments were performed for
HDAC10, as this candidate was not initially identified within
the TOP10 list (Supplementary Figures S3b and c). Con-
sistent with the upregulation of their transcripts, greater
quantities of all five proteins were found in treatment-resistant
3D- compared to 2D-cultured BE(2)-C cells (Figure 4f).
Three-dimensional cell culture increases autophagic
flux. It has been proposed that tumor cells adopt autophagy
as a survival mechanism to cope with metabolic and cyto-
toxic stress.15,35,36 Similarly, spheroid cultures might use this
survival strategy, especially in the inner starved zones.33 We
examined autophagic flux in our standardized 3D-chip culture
using stably transfected BE(2)-C cells expressing the tandem
construct mCherry-EGFP-LC3B. Appearance of red dots
indicates activated autophagic flux, characterized by suc-
cessful fusion of autophagosomes with lysosomes, forming
low-pH autolysosomes where acid-sensitive green fluores-
cence is lost. Three-dimensionally grown BE(2)-C cells
clearly showed characteristic LC3 punctate staining with
red mCherry, but not green EGFP fluorescence (Figure 5a).
In contrast, EGFP fluorescence was detected upon treating
3D-grown cells with the flux-inhibiting lysosomotropic agent
chloroquine (CQ), resulting in yellow punctae in the merged
image (Figure 5a). Inhibition of autophagic flux by CQ also
increased the amount of propidium iodide-positive dead
cells inside the 3D structure (Figure 5b), further hinting at a
pro-survival role of autophagy in spheroids. As an indi-
cator for metabolic stress-induced autophagy and auto-
phagosome formation, we analyzed mTOR activity and
determined WIPI1 mRNA expression levels37 as well as
LC3-phosphatidylethanolamine (LC3-II) conjugation. Three-
dimensionally grown BE(2)-C cells displayed decreased
levels of p-mTOR, reflected in decreased phosphorylation
of its substrate, S6K (Figure 5c, Supplementary Figure S3d),
upregulated WIPI1 (Figure 5d) and displayed an increased
LC3-II/LC3-I-ratio compared to 2D cultures (Supplementary
Figure S3e and f). Depletion of ATG5 inhibited autophagy
initiation, detected by lack of LC3-II (Figure 5e, Supple-
mentary Figure S3e). Moreover, BE(2)-C cell spheroids
Table 1 TOP10 of regulated autophagy genes.
Gene name 3Da versus 2D Illumina
Array ‘autophagy’
(GO:006914)
P-value
3Da versus 2D
real-time PCR
(SDHA normalized)
P-valueb
Tumorc versus 2D
real-time PCR
(SDHA normalized)
P-valueb
Tissuedversus cell
linee R2 database
(SDHA normalized)
P-value
Tissued versus
cell linee R2
database
P-value
ULK1 o0.0001 ↑ 0.0108 ↑ 0.0206 ↑ 0.0009 ↑ n.s. —
MAPT o0.0001 ↑ 0.0404 ↑ 0.0070 ↑ o0.0001 ↑ o0.0001 ↑
HDAC6 0.0003 ↑ 0.0002 ↑ 0.0236 ↑ o0.0001 ↑ o0.0001 ↑
PIM2 0.0003 ↑ 0.0379 ↑ 0.0321 ↑ 0.0085 ↑ n.s. —
RAB24 0.0005 ↑ 0.0219 ↑ 0.0239 ↑ 0.0021 ↑ n.s. —
ABL1 0.0006 ↑ 0.0268 ↑ n.s. — n.s. — 0.02 ↓
MAP1LC3A 0.0006 ↑ 0.0175 ↑ 0.0067 ↑ o0.0001 ↑ o0.0001 ↑
ATG16L2 0.0009 ↑ 0.0474 ↑ 0.0006 ↑ 0.0008 ↑ 0.0095 ↑
ATG3 0.0010 ↓ n.s. — 0.0225 ↓ n.s. — 0.0013 ↓
NPC1 0.0012 ↑ 0.0210 ↑ 0.0439 ↑ o0.0001 ↑ 0.0057 ↑
HDAC10 n.d. 0.0011 ↑ 0.0075 ↑ o0.0001 ↑ 0.0008 ↑
Abbreviations: n.d., not determined; n.s., not significant
a3D comprises 3D and 3D bioreactor samples
bOne-sample t-test to test whether means of 3D samples or tumor samples, respectively, are significantly different from 1.0
c Three individual neuroblastoma patient samples with characteristics resembling BE(2)-C cells (stage 4, MYCN amplified, 1p-deleted, undifferentiated)
dMYCNamp neuroblastoma tissue samples (n= 16) from data set of mixed neuroblastoma cell lines/tissues (Versteeg) contained in the web-based R2 microarray
database (http://r2.amc.nl)
eMYCNamp neuroblastoma cell lines (n= 15) from data set of mixed neuroblastoma cell lines/tissues (Versteeg) contained in the web-based R2 microarray database
(http://r2.amc.nl)
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Figure 4 Elevated expression of autophagy-related genes in 3D cultures and tumors compared to 2D monolayer cultures. (a) Comparison of gene expression profiles from 15
MYCN-amplified neuroblastoma cell lines (red) and 16 MYCN-amplified neuroblastoma tissue samples (green) via the web-based R2 microarray database (http://r2.amc.nl) and
the data set of mixed neuroblastoma cell lines/tissues (‘Versteeg’). The PCA was performed with all genes associated with the GO term ‘macroautophagy’. The first two principal
components, PC1 and PC2, are shown. (b) Heatmap for validation of the TOP10 gene list with MYCN-amplified neuroblastoma cell lines (red) and MYCN-amplified
neuroblastoma tissue samples (green) via the web-based R2 microarray database (http://r2.amc.nl) and the data set of mixed neuroblastoma cell lines/tissues (‘Versteeg’).
(c) Heatmap showing expression of a subset of genes associated with the GO term 'autophagy' (GO:006914) in 2D- and 3D-cultured BE(2)-C cells and in neuroblastoma tumor
tissue. Genes included are those with a component P-value less than 0.005 based on a globaltest analysis. Hierarchical clustering analysis, visualized as dendrograms on the left
side of the heatmap, shows that the 2D samples cluster separately from the 3D and tumor samples. (d) Euler diagram displaying the overlap of significantly deregulated TOP10
genes in the three validation cohorts: 1) real-time PCR measurements of TOP10 genes in 3D- versus 2D- grown BE(2)-C cells; 2) real-time PCR measurements of TOP10 genes
in three NB tumors (stage 4,MYCN-amplified) versus 2D- grown BE(2)-C cells; 3) web-based R2 microarray database (http://r2.amc.nl) with the data set of mixed neuroblastoma
cell lines/tissues (‘Versteeg’). (e) Comparison of the expression of the TOP10 gene list plus HDAC10 in BE(2)-C cells grown for 6 d in 2D (dotted normalization line; PCR) and 3D/
3D-BR (blue; PCR) conditions, three neuroblastoma patient samples (tissue; magenta; PCR), as well as web-based (R2) microarray data from MYCN amplified neuroblastoma
cell lines (red) and MYCN-amplified neuroblastoma tissue samples (green). All data were normalized to the respective 2D samples and neuroblastoma housekeeping gene
SDHA. The PCR data were normalized in each experiment to 2D, thus the 2D expression values are equal to one across experiments. A second housekeeping gene, HPRT,
served as normalization control. (f) Western blot presenting expression levels of the proteins ULK1, HDAC6, MAP1LC3A, ATG16L2, and HDAC10 in 2D- and 3D-cultured BE(2)-C
cells. Numbers indicate expression relative to 2D and normalized to β-actin expression
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displayed CYTO-ID-positive cells38 in the inner region, which
were further enriched upon treatment with CQ. Depletion of
ATG5 decreased CYTO-ID labeling of autophagic compart-
ments upon CQ treatment (Figure 5f). Inhibition of late
autophagic flux through application of CQ (Figure 5g) or
bafilomycin A1 (Figure 5h and Supplementary Figure S3f)
increased the amount of LC3-II, further pointing towards an
enrichment of autophagy under 3D conditions. In contrast, in
drug-sensitive NB-1 cells (Figure 2f), LC3-II was undetect-
able and could not be induced by bafilomycin or 3D growth
3D models mimic pathophysiological autophagic ﬂux
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(Figure 5i), indicating a relative deficiency in autophagy
initiation. In contrast to autophagy-competent BE(2)-C cells,
ULK1, LC3A, ATG16L2 and HDAC6/10 were not enriched
in 3D-grown NB-1 cells (Supplementary Figure S3g).
Finally, 3D-grown BE(2)-C cells exhibited depletion of the
autophagy substrate sequestosome 1 (p62/SQSTM1), which,
together with SQSTM1 enrichment upon autophagy inhibition
with CQ, implies more active autophagosomes (Figure 5g).
These results indicate that 3D culture conditions enhance
preexisting autophagic flux in autophagy-competent neuro-
blastoma cells.
Transcriptional regulation of autophagy. As elevated
expression of autophagy genes points towards transcriptional
upregulation, we investigated six transcription factors known
to regulate the expression of autophagy-related genes.39–42
All transcription factors, except NRF2 (NFE2L2), showed
elevated expression in tumors compared to 2D cell lines. Our
3D cultures expressed four of the transcription factors at a
level between that of 2D and tumor samples, showing that 3D
growth alters expression in the same direction seen in tumors
(Figure 6a). Additionally, FOXO3 expression significantly
correlated with the expression of seven TOP10 genes plus
HDAC10 (Supplementary Table 4). Three-dimensionally
cultured BE(2)-C, but not NB-1 cells, displayed increased
protein levels of FOXO3 (Figure 6b). Depletion of FOXO3 in
3D-cultured BE(2)-C cells altered expression of seven genes
plus HDAC10 as well as GABARAPL1, a well-known FOXO3
target gene43 (Figure 6c; exemplarily shown on protein level
for HDAC6, ATG16L2 and HDAC10; Figure 6d).
We employed an siRNA-mediated knock-down approach to
further validate the role of autophagy regulators and HDACs in
mediating therapeutic resistance of 3D cultures. Three-
dimensionally grown BE(2)-C cells depleted of BECN1,
ATG5, ATG7, HDAC6, HDAC10 and FOXO3 exhibited
impaired autophagic flux, demonstrated by SQSTM1 accu-
mulation (Figure 6e) and increased chemotherapeutic sensi-
tivity close to the level seen in 2D cultures, potentiating
the effects of vincristine (Figures 6f and g), though HDAC6
depletion achieved comparatively weak effects. The same
approach also sensitized 2D-grown cells, however the
combination exhibited no potentiation effect (except HDAC10;
Supplementary Figure S4a). As 2D cell viability was not
decreased by siRNA knockdown alone (except HDAC10),
the more pronounced effects on viable cell number 6 d after
transfection can be explained by the higher proliferation rate of
2D-grown cells (Supplementary Tables 2 and 5). Thus,
transcriptional activation of autophagy supports enhanced
expression of autophagy-related genes in 3D models and
cancer tissues. Furthermore, the data suggest that inter-
ference with autophagy is a promising approach to break
therapy resistance in neuroblastoma cells.
Pharmacological inhibition of autophagic flux sensitizes
3D-grown neuroblastoma cells to cytotoxic treatment.
Based on our findings that 3D-grown cells are sensitized to
cytotoxic treatment when genetic interference disrupts
autophagic flux, we explored whether a pharmacological
block would yield similar results. To pharmacologically inter-
fere with late-stage autophagy, we used chloroquine (CQ)
and bufexamac, a class IIb HDAC inhibitor (Supplementary
Figure S4b). Bufexamac impaired autophagic flux, demon-
strated by an increased quantity of yellow mCherry-EGFP-
LC3B dots, elevated SQSTM1 and LAMP-2 levels (Supple-
mentary Figures S4c and d).
Co-treatment of 3D-grownBE(2)-C cellswith vincristine plus
either CQ (Figure 7a) or bufexamac (Figure 7b) induced cell
death, detected via effector caspase activity assay. Caspase-3
activation was further confirmed by detection of PARP
cleavage in BE(2)-C (Figure 7c) and IMR-32 (Figure 7d) cells.
Similarly, co-treatment of 3D-grown BE(2)-C cells with
doxorubicin plus either CQ or bafilomycin further decreased
viable cell number, with a greater potentiation effect in 3D-
grown compared to 2D-grown cells (Supplementary Figures
S4e–g).
The IC50 values for vincristine (100 ng/ml) and doxorubicin
(540 ng/ml) were decreased 15- to 100-fold upon combination
with CQ or bufexamac (Figures 7e and f). These results
demonstrate that co-treatment is able to shift effective
concentrations into a range that is clinically achievable in
patient plasma (doxorubicin: approximately 60 ng/ml; vincris-
tine: approximately 7 ng/ml).44,45 Co-treatment of 3D cells
Figure 5 Detection of autophagic flux in cells grown under 3D culture conditions. (a) Fluorescence microscopic detection of autophagosome-lysosome fusion in stable
mCherry-EGFP-LC3B BE(2)-C cells cultured under 3D conditions for 72 h. Yellow dots in the merged picture indicate autophagosomes only, whereas red-only signals indicate
successful fusion to autophagolysosomes. CQ: chloroquine (25 μM, 6 h). Graphs display ImageJ-based quantification of red or green dots/picture, respectively. Red-to-green
ratio for 3D: 24.8±10.9 (S.E.M.). Red-to-green ratio for 3D plus CQ: 0.9± 0.1 (S.E.M.). (b) In-chip fluorescence microscopic detection of dead BE(2)-C cells cultured under 3D
conditions for 72 h. Red signals indicate propidium iodide (PI) positive cells. CQ: chloroquine (48 h). Graphs display ImageJ-based quantification of red dots/cavity. (c) Western
blot displaying p-mTOR and P-S6K1 protein levels. BE(2)-C cells were grown as monolayers (2D) or in 3D culture for 7 days. GAPDH served as a loading control. (d) BE(2)-C
cells were grown under 2D or 3D conditions and the mRNA expression levels of WIPI1 were detected using real-time PCR as an indicator of autophagosome formation. SDHA
and HPRT served as housekeeping genes. Bars represent mean values, error bars represent S.E.M. A one-sample t-test was performed to check whether the mean of 3D
samples differs significantly from the value 1.0. *Po0.05. (e) Western blot displaying the conversion of LC3-I to LC3-II upon knockdown of ATG5 expression. Negative control
transfected cells are indicated with a minus sign. BE(2)-C cells were grown as monolayers (2D) or in 3D culture. Numbers indicate ATG5 expression relative to negative control
transfected 2D cells and normalized to β-actin expression (upper row) and the ratio of LC3-II to LC3-I (lower row). (f) Left: Representative pictures of CYTO-ID (green) and
Hoechst (blue) co-stained 3D structures, treated with chloroquine (CQ), where indicated. Confocal microcopy pictures from the bottom, middle and top region of the 3D structure
are presented. Right: Bar diagram. Quantification of CYTO-ID high cells (blank-corrected mean fluorescence) determined by FACS analysis. BE(2)-C cells were transfected with
negative control (NC) or ATG5 siRNA, respectively and treated with chloroquine (CQ), where indicated. (g) Western blot displaying SQSTM1 protein levels as well as the
conversion of cytoplasmic LC3-I to autophagosome-associated LC3-II. Where indicated chloroquine (CQ, 25 μM, 5 h) was added. BE(2)-C cells were grown as monolayers (2D)
or in 3D culture. Numbers indicate SQSTM1 expression, relative to 2D and normalized to β-actin expression as well as the ratio of LC3-II to LC3-I. (h,i) Western blot displaying the
conversion of LC3-I to LC3-II. Where indicated, bafilomycin A1 (BAF, 100 nM, 4 h) was added. BE(2)-C (h) and NB1 (i) cells were grown as monolayers (2D) or in 3D culture.
Numbers indicate the ratio of LC3-II to LC3-I. *nonspecific band
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Figure 6 Transcriptional regulation of autophagy-related genes. (a) Boxplots comparing the expression of autophagy-related transcription factors in BE(2)-C cells grown for
6 days in 2D (dotted normalization line; Illumina) and 3D/3D-BR (blue; Illumina) conditions, three neuroblastoma patient samples (tissue; magenta; Illumina), as well as web-
based (R2) microarray data fromMYCN-amplified neuroblastoma cell lines (red) andMYCN-amplified neuroblastoma tissue samples (green). All data sets (web-based R2 as well
as Illumina microarray expression data) were normalized to the respective 2D samples and neuroblastoma housekeeping gene SDHA. (b) Western blot presenting expression
levels of FOXO3 in 2D- and 3D-cultured BE(2)-C cells or NB-1 cells, respectively. Numbers indicate expression relative to 2D and normalized to β-actin. (c) Heatmap displaying
expression levels of TOP10 genes plus HDAC10 and the well-known FOXO3 target gene GABARAPL1 upon knockdown of FOXO3 expression in 3D-grown BE(2)-C cells 6 d
after transfection and measured by real-time PCR. Negative control transfected cells are indicated with a minus sign. (d) Western blot: detection of FOXO3, HDAC6, ATG16L2 and
HDAC10 protein levels in FOXO3 siRNA transfected 3D-grown BE(2)-C cells. β-Actin served as a loading control. Numbers indicate FOXO3, HDAC6, HDAC10 or ATG16L2
expression, respectively, relative to NC transfected cells and normalized to β-actin expression. NC: transfected with negative control siRNA. (e) Western blot displaying SQSTM1
protein levels of BE(2)-C cells grown as 3D cultures for 6 d upon knockdown of Beclin-1 (BECN), ATG5, ATG7, HDAC6 or HDAC10 expression. Negative control transfected cells
are indicated with a minus sign. Numbers indicate SQSTM1 expression (upper row) or target expression (lower row) relative to negative control transfected 3D cells and
normalized to β-actin expression. *nonspecific band (f) BE(2)-C cells were grown under 2D conditions for 6 d and treated with vincristine (10 ng/ml) where indicated for the last
96 h. (g) BE(2)-C cells were transiently transfected with siRNAs targeting Beclin-1 (siBECN, pink), ATG5 (light blue), ATG7 (grey), HDAC6 (siHD6, blue), HDAC10 (siHD10, mint
green) or FOXO3 (orange), respectively. After transfection, cells were grown under 3D conditions for 6 d and treated with vincristine (10 ng/ml) where indicated for the last 96 h.
(f,g) Relative cell number, meaning viable cells/ml normalized to solvent treated NC siRNA transfected control were determined with an automated cell counter. Green shading
indicates effect ± S.E.M. of vincristine in 2D, NC siRNA transfected cells NC siRNA: transfected with negative control siRNA. Bars represent mean values, error bars represent
S.E.M. Significant differences between groups were tested using an unpaired, two-tailed t-test. *Po0.05; **Po0.01; ***Po0.001
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Figure 7 Pharmacological inhibition of autophagic flux sensitizes three-dimensional cell culture to treatment-induced cell death. (a) Cells were treated with chloroquine
(25 μM) and vincristine (10 ng/ml) for the last 48 h, where indicated. (b) Cells were treated with bufexamac (30 μM) and vincristine (10 ng/ml) for the last 48 h, where indicated.
(a and b) BE(2)-C cells grown under 3D-static conditions for 4 days. Caspase-3 (DEVDase) activity was measured using a fluorometric assay with activity (slope/min) measured
relative to untreated cells. Bars represent mean values of at least three independent experiments, error bars represent S.E.M. Significant differences between groups were tested
using an unpaired, two-tailed t-test. **Po0.01; ***Po0.001. (c,d) Western blot analysis of PARP cleavage in 3D-grown cells. Cells were cultured for a total of four days, with
treatment starting 72 h (CQ, BUF) or 48 h (VINC) before lysate preparation. β-Actin served as a loading control. Numbers indicate the ratio of cleaved to full-length PARP. cl.,
cleaved; f.l., full-length. (c) BE(2)-C cells treated with vincristine (VINC, 10 ng/ml), chloroquine (CQ, 25 μM) and bufexamac (BUF, 30 μM) where indicated. (d) IMR-32 cells
treated with vincristine (VINC, 3 ng/ml), chloroquine (CQ, 25 μM) and bufexamac (BUF, 30 μM) where indicated. (e-f) Three-dimensionally grown (3D) BE(2)-C cells were treated
with chloroquine (CQ, 25 μM, 72 h) or bufexamac (BUF, 30 μM, 72 h) and vincristine (VINC, 48 h) (e) or doxorubicin (DOXO, 48 h) (f) in various concentrations. IC50 values were
calculated with GraphPad Prism (function: log(inhibitor) versus normalized response; variable slope). Number of viable cells was assessed by automated cell counting and trypan
blue exclusion and normalized to untreated cells. (g,h) One day after seeding, chips containing 3D-cultured BE(2)-C (g) or IMR-32 (h) cells were transferred into the bioreactor
system (3D-BR) and medium or medium containing compounds was pumped through the system for 48 h. Where indicated, vincristine (VINC, 10 ng/ml, 48 h) or bufexamac (BUF,
30 μM, 48 h) was applied. Results are displayed as means of at least three independent experiments. Error bars represent S.E.M. Significant differences between groups were
tested using an unpaired, two-tailed t-test. *Po0.05; **Po0.01. (i) BE(2)-C cells were grown as 2D or 3D culture and treated with doxorubicin (0.5 μg/ml) for 48 h. (j) BE(2)-C
cells were grown as 3D culture, treated with doxorubicin (0.5 μg/ml) for 48 h and co-treated with chloroquine (CQ, 5 μM) or bufexamac (BUF, 30 μM) where indicated. (i,j) Mean
fluorescence was detected by flow cytometry. Bars represent mean values, error bars represent S.E.M. Significant differences between groups were tested using a paired, two-
tailed t-test. **Po0.01; *Po0.05
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transferred into the bioreactor system with bufexamac also
significantly decreased the quantity of viable cells (Figure 7g)
and increased cell death (Figure 7h).
Decreased intracellular doxorubicin, due to the 3D culture
itself, the thereby increased autophagic flux, or a combination
of both factors, could be one possible mechanism involved in
resistance to cytotoxic treatment. Hence, we exploited the
inherent fluorescence of doxorubicin to quantify intracellular
doxorubicin by FACS in 2D and 3D cultures. Doxorubicin
fluorescence was significantly decreased in 3D cultures
(Figure 7i), while co-treatment with CQ and bufexamac
reversed this effect (Figure 7j), yielding comparable levels
achievable in 2D cultures (Figure 7i). Likewise, intracellular
doxorubicin concentration was enriched when cells were
depleted of FOXO3, ATG5 or HDAC10 (but not HDAC6)
(Supplementary Figure S4h). These results demonstrate the
substantial impact of autophagy on drug response at two
levels: i. cell survival and ii. decreased intracellular drug
concentration (as shown for doxorubicin), suggesting that
pharmacological inhibition of autophagic flux effectively
sensitizes 3D-grown cells to cytotoxic treatment.
Discussion
Drug screens in 2D systems have successfully identified
compounds that were subsequently translated into clinical
use. Notable examples are inhibitors targeting tyrosine
kinases, such as ALK (crizotinib), Bcr-Abl (imatinib) and
HER2 (trastuzumab), which are aberrantly active due to
genetic alterations.46–49 Nevertheless, there is a poor correla-
tion between effectiveness of emerging anti-cancer agents in
cell culture and ultimate treatment success rates in patients,
which are low and need improvement.50 Culture conditions
impact the regulation of cell fate and responsiveness to
external stimuli. Two-dimensional cultures are favored due to
high-throughput testing capability, but may lose phenotypic
and functional characteristics,5 which can be overcome by
culturing cells under more physiological 3D conditions. A
remaining practical challenge is large-scale testing of com-
pound libraries, under reproducible 3D conditions. The chip-
based system used here yields 3D cultures with a well-defined
and consistent geometry, stable and comparable culture
conditions, and compatibility with a bioreactor system,
allowing for an even more representative environment.
Several DNA microarray studies demonstrated significant,
tumor-relevant molecular changes induced by 3D growth.3
Our gene expression studies corroborate these results and
show that 3D growth affects the expression of ATG genes and
autophagy-controlling transcription factors, such as TFEB and
FOXO3. FOXO transcription factors are regulated by a wide
range of external stimuli, including nutrients and oxidative
stress,51 and can support stress resistance through induction
of antioxidant as well as ATG proteins.52 Our results indicate
that autophagy and the expression of ATG genes may be
induced as an adaptive survival strategy due to stress
conditions inside the 3D structure, which is also reflected in
strongly reduced mTOR activity. Several publications indicate
that there is cross-talk between the activity of the mTOR
complexes and the activity of FOXO3a via AKT, which can be
activated by mTORC2.53 AKT, in turn, negatively regulates
FOXO3a by phosphorylation, preventing its nuclear
translocation.54 Thus, it is conceivable that reduced activity
of the mTORC/AKT axis supports FOXO3 transcriptional
activity in our model system. Overall, autophagy induction
protects the cells, as co-treatment with autophagic flux
blockers increases sensitivity of 3D cultures to chemotherapy.
This is in line with several studies demonstrating that inhibition
of autophagy sensitizes a diversity of tumor entities towards
chemotherapeutic drugs in vitro and in vivo.55–58 Accordingly,
several early phase clinical trials are currently under way to
evaluate autophagy inhibition using (hydroxy-)chloroquine in
combination with chemotherapy or targeted agents.58,59
Unraveling the exact mechanism as to how autophagy is
protecting which type of tumor cell is the subject of current
research, which also indicates a particular role for lysosomes
as mediators of drug resistance.60
Although technically different 3D culture systems are similar
in terms of more tissue-like cell morphology,3 the role of
autophagy might depend on tumor entity, tumor stage and 3D
culture context. For example, in contrast to our 3D model, the
3D laminin-rich ECMmodel resulted in increased sensitivity to
doxorubicin and compromised autophagy.61
Accurate determination of susceptibility to treatment is crucial
for preclinical assessment of a compound’s efficacy. In our
setting, 2D-grown BE(2)-C cells are sensitive to doxorubicin
and vincristine in clinically achievable concentrations, while the
3Dmodel predicts resistance.44,45 Consistent with the latter, the
BE(2)-C cell line was isolated from a relapsed neuroblastoma
patient following multi-agent chemotherapy, including
doxorubicin.62 Cytotoxic drugs combined with autophagy
inhibitors shifted the effective chemotherapy concentrations
back to clinically achievable levels. We observed, at least in the
case of doxorubicin, that sensitization is accompanied by an
increased uptake (or decreased efflux) of the cytotoxic drug into
the 3D structure and that inhibition of autophagy plays an
important role in this effect. However, we cannot exclude that
additional, potentially drug-specific mechanisms account for
the beneficial effects of combination treatment. Overall, 3D
models decrease the discrepancy between cell culture and
tumor tissue and are useful for the identification of points of
vulnerability for cancer treatment. Our work with 3D cultures
underscores two critical aspects, which are (at least partly)
linked together: (i) the upregulation of cell-protective autophagy
and (ii) decreased intracellular drug concentration.
Altogether, our data favor 3D cell cultures as tissue-like
models, recapitulating solid tumors with respect to cell
morphology, gene expression and cellular functions. The
inclusion of 3D models is highly advantageous, particularly for
mechanistic studies and investigations of drugs targeting the
autophagic pathway.
Materials and Methods
3D and 2D cell cultures and patient samples. Human neuroblastoma
cell lines BE(2)-C (ECACC), IMR-32 (DSMZ) and the tetracycline-inducible
shMYCN IMR5/7563 (generously provided by the laboratory of F. Westermann) were
cultured under standard conditions (DMEM with L-glutamine and 4.5 g/l glucose
containing 10% FCS (Sigma) and 1% non-essential amino acids (NEAA; Invitrogen,
Darmstadt, Germany)). Human neuroblastoma cell lines SK-N-BE, NB-1
(#RCB1953, RIKEN cell bank, Japan) and Kelly (DSMZ) were cultured in RPMI
with L-glutamine containing 10% FCS (Sigma, Taufkirchen, Germany) and 1% non-
essential amino acids (NEAA; Invitrogen). Wildtype and HDAC10-knockout
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HAP1 cells (Horizon Discovery Group, Cambridge, UK) were cultured in Iscove's
Modified Dulbecco's Medium (IMDM) with 10% FCS (Sigma). All cell lines were
regularly checked for contamination (Multiplexion, Heidelberg, Germany) and
verified using DNA fingerprinting authentication by the DSMZ, Germany. The 3D
cultures were prepared on ridged scaffolds (MatriGrid structures), with a total active
area of 5 × 5 mm2, as described previously.9,64 Briefly, the microcavity-containing
polymeric scaffolds, each with a diameter of 300 μm and a depth of 207 μm,64 were
coated with collagen type I (10 μg/cm2, Sigma, #C3867) as substratum, allowing
cells to adhere to the scaffold. After 2 h of drying, cell solution was added to the
prepared chip. For the static 3D model, cells were cultured on 3D scaffolds for 3–
7 days, as indicated in the respective figure legend. For the bioreactor system, cells
were cultured on 3D scaffolds for 2 days, then the cell-containing chips were
inserted into the bioreactor cube9,64 and cultured for another 2–5 days, as indicated
in the respective figure legend. Complete medium containing test compound or
solvent control was pumped through the bioreactor system (Ismatec, Wertheim,
Germany) with a flow rate of 25–35 μl/min. If necessary, the spheroids were
recovered from the cavities by trypsinization (3–4 min at 37 °C) and one to
maximum two very careful washing steps with fresh medium.
Generation of stable cells: Human BE(2)-C cell lines stably expressing
mCherry-EGFP-LC3B were established by transfection using Effectene (Qiagen,
Hilden, Germany) with the mCherry-EGFP-LC3B construct (no. 22418; Jayanta
Debnath) from Addgene. Transfected cells were selected with puromycin (2 μg/ml)
for 3 weeks. A mixed population of puromycin-resistant cells was used for
experimental analysis.
Patient samples: The three neuroblastoma patient samples from the German
Neuroblastoma Trials NB90-NB200430 were obtained from the German Society of
Pediatric Oncology and Hematology Tumor Bank and Neuroblastoma Study Center
(Cologne, Germany). All of the patients were registered with the German
neuroblastoma study and written informed consent was obtained.30 The three tumor
samples were chosen to resemble the characteristics of BE(2)-C cells, which
are derived from a stage 4, MYCN amplified, 1p-deleted, undifferentiated tumor of
a 2-year-old child. Tumor sample #1: stage 4, MYCN amplified, 1p-deleted,
undifferentiated, age at diagnosis: 279 days. Sample #2: stage 4, MYCN amplified,
1p-deleted, poorly differentiated, age at diagnosis: 121 days. Sample #3: stage 4,
MYCN amplified, 1p-deleted, undifferentiated, age at diagnosis: 536 days.
Reagents and transfection. Bufexamac (100 mM stock),65 bafilomycin A1
(10 μM stock) and rapamycin (1 mM stock) were obtained from Sigma and
dissolved in DMSO. Chloroquine (Sigma; 100 mM stock), doxorubicin (Biozol,
Eching, Germany; 1 mg/ml stock), and vincristine (Enzo Life Sciences, Lörrach,
Germany, 5 mM stock) were dissolved in H2O. Cisplatin (Axxora, Lörrach, Germany;
15 mg/ml stock), etoposide (Enzo Life Sciences; 10 mg/ml) and crizotinib
(Selleckchem, Houston, USA; 10 mM), were dissolved in DMSO. Commercially
available siRNAs were used for transient transfections (pooled): HDAC10 #33581
and #120681 (Ambion, Huntingdon, UK), HDAC6 #120451 and #120450 (Ambion),
ATG5 HS_APG5L_6 and HS_APG5L_3 FlexiTube siRNA (Qiagen, Hilden,
Germany), ATG7 Hs_APG7L_5 FlexiTube siRNA (Qiagen), FOXO3 #s5260,
s5262, s5261 (pooled, Ambion) and BECN1: Hs_BECN1_5 FlexiTube siRNA
(Qiagen). The following sequence was additionally chosen to specifically target
BECN1: 5′-CAG UUU GGC ACA AUC AAU Att-3′ (Beclin 1 sense); 5′-
UAU UGA UUG UGC CAA ACU Gtt-3′ (Beclin 1 antisense). The NC siRNAs
(Silencer Negative Control #1 and Silencer Negative Control #5; Ambion) were used
as negative controls. Transfection was performed as described previously12 in 2D
monolayer cultures and cells were transferred 24 h after transfection into the 3D
model. The percentage of siRNA-transfected BE(2)-C cells was 90% as determined
by fluorescently-labeled siRNA siGLO Lamin A/C (Dharmacon).
Immunoblotting and fluorescent microscopy. Western blot analysis
was performed as previously described.66 The following antibodies were used: anti-
LC3B (L7543; Sigma), anti-p62/SQSTM1 (MBL-M162-3B), anti-HDAC6 (sc-11420,
Santa Cruz), anti-HDAC10 (H3413, Sigma), anti-PARP (4C10-5; BD Pharmingen,
Heidelberg, Germany), anti-Beclin-1 (D-18; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-FOXO3A (2497 s, Cell Signaling), anti-LAMP2 (H4B4; Santa Cruz
Biotechnology), anti-acetylated tubulin (6-11B-1; Sigma), anti-GAPDH (JC1682928,
Millipore, Darmstadt, Germany), anti-ULK1 (#8054; Cell Signaling), anti-ATG16L2
(AP11695c-AB; Abgent), anti-MAP1LC3A (AP1805a; Abgent, San Diego, CA, USA),
anti-ATG5 (#2630; Cell Signaling, Leiden, Netherlands), anti-ATG7 (#2631, Cell
Signaling), anti-p-mTOR (Ser2448; Upstate), anti-p-S6K1 (Thr412; Upstate) and
anti-β-actin (clone AC-15; Sigma). Ratios were calculated with the Bio-1D Version
12.10a software (Peqlab, Erlangen, Germany).
Fluorescence microscopy: Stable mCherry-EGFP-LC3B BE(2)-C cells were
viewed using the × 63 objective on a Zeiss LSM700 laser scanning confocal
microscope. For quantification, the Image-based Tool for Counting Nuclei (ITCN) in
ImageJ software (U. S. National Institutes of Health, Bethesda, MD, USA; http://
imagej.nih.gov/ij/) was used on 8-bit pictures (threshold adjusted to 15, 255 for
green dots and 25, 255 for red dots).
Imaging of CYTO-ID stained spheroids: BE(2)-C cells were seeded in 3D
scaffolds and grown for 2 days. On the night before treatment, chips were
transferred to 8-well μ-Slides (Ibidi) and treated with control medium (DMEM w/o
phenol-red 10%FCS 1% NEAA) or 5 μM CQ. Slides were carefully washed twice
with 1x Assay Buffer+5% FCS and stained with 200 μl/well CYTO-ID staining
solution (1 × assay buffer, 5% FCS, 2 μl CYTO-ID, 1 μl Hoechst 33352; Enzo Life
Sciences) for 30 min at 37 °C. Chips were carefully washed and imaged on a Zeiss
LSM710 confocal microscope (Jena, Germany).
Immunohistochemistry and nuclear staining: Immunohistochemistry and
nuclear staining were performed on BE(2)-C cells grown under 2D or 3D conditions,
and a neuroblastoma tissue sample. Briefly, cells were fixed with ice-cold methanol
for 20 min and stained with hematoxylin and eosin (HE) or diamidino-2-phenylindole
(DAPI). Before staining, spheroids were freed from the polymeric chip by
trypsinization (4 min at 37 °C), followed by careful transfer onto glass slides after
addition of medium. The neuroblastoma tissue sample (#14T1OL) was provided by
the tissue bank of the National Center for Tumor Diseases (NCT, Heidelberg,
Germany) in accordance with the regulations of the tissue bank and with the
approval of the ethics committee of Heidelberg University. Sections were
deparaffinized, incubated with Tris-buffer saline containing 0.5% Triton X-100 (TBST)
for 20 min at room temperature. Following staining with HE or Hoechst dye (30 min
at room temperature), the slides were washed and mounted. Fluorescent images
were acquired on a Zeiss LSM 710 confocal microscope using the 40 × objective.
Quantification of CYTO-ID via flow cytometry: Three days after siRNA
transfection, BE(2)-C cells were seeded in 3D scaffolds and grown for an additional
72 h. Where indicated, cells were treated with 5 μM CQ the night before staining
with CYTO-ID (Enzo Life Sciences). For staining (6 d post-siRNA transfection),
chips were washed once with medium w/o phenol red, transferred to a fresh 6-well
plate and covered with 500 μl CYTO-ID staining solution (1 × assay buffer, 5% FCS,
1 μl CYTO-ID) for 30 min at 37 °C. Cells were washed with medium w/o phenol red,
trypsinized (4 min. 37 °C), centrifuged and washed again in cold medium w/o
phenol-red. CYTO-ID fluorescence was quantified on a BD FACSCanto II platform
using an Alexa488 filter setting
Quantification of doxorubicin uptake: BE(2)-C cells were seeded in 3D
scaffolds 24 h prior to treatment. Spheroids were treated for 48 h with solvent
control (DMSO), doxorubicin (500 ng/ml), combinations of doxorubicin with
bufexamac (30 μM), chloroquine (5 μM) or both. For the knockdown approach,
BE(2)-C cells were seeded in 3D scaffolds three days after transfection with ATG5,
FOXO3a, HDAC6, HDAC10 or control siRNAs, grown for an additional 48 h and
treated with 500 ng/ml doxorubicin 24 h before staining. For FACS analysis, chips
were washed with RPMI w/o phenol red (10% FCS), transferred to a fresh 6-well
plate, trypsinized (4 min, 37 °C), centrifuged and washed again in cold medium w/o
phenol-red (10% FCS). For the analysis of 2D conditions, BE(2)-C cells were
seeded in monolayers in six-well plates 24 h prior to treatment. Thereafter, the
same protocol as for the 3D scaffolds was followed. Doxorubicin fluorescence was
quantified on a BD FACSCanto II platform using a Phycoerythrin (PE) filter setting.
Cell counting, cell viability and cell death assays. For cell death
detection, adherent as well as floating cells were collected.
Viability assay: Trypsinized cells were pooled with corresponding supernatant,
centrifuged and resuspended in 1 ml cell culture media. Cell viability was measured
by automated trypan blue staining with the Vi-Cell XR Cell Viability Analyzer from
Beckman Coulter (Krefeld, Germany).
3D models mimic pathophysiological autophagic ﬂux
C Bingel et al
13
Cell Death and Disease
Nicoletti staining: Cell death quantification by flow cytometry was performed as
described previously.67
Caspase protease activity assay. DEVDase or IETDase activity was measured with
the Caspase-3 or Caspase-8 Fluorometric Assay (BioVision), respectively,
according to the manufacturer’s protocol.
PARP cleavage. For detection of Poly(ADP-ribose) polymerase (PARP) cleavage,
anti-PARP (4C10-5; BD Pharmingen) was used.
RNA-Isolation, microarray analysis and real-time PCR. Total RNA
was isolated from three independent human neuroblastoma tissue samples (see
above) or 2D, 3D-static and 3D bioreactor neuroblastoma cell cultures (each in
triplicate), using the RNeasy MiniKit (Qiagen). For microarray analysis, 1 μg RNA
per sample was used. Gene expression analysis was performed at the house-
internal Genomics and Proteomics Core Facility using human whole genome HT-12
v4 BeadChips. Normalization of the raw intensity data was performed by the
microarray unit of the DKFZ Genomics and Proteomics Core Facility with Illumina
BeadStudio Data Analysis Software version v4_r2. The normalized gene expression
profiles were further analyzed by principal components analysis (PCA) using the
statistical software R.68 For analysis of autophagy transcription factor expression the
following probesets were applied: FOXO3: ILMN_1844692; HIF1A: ILMN_2379788;
MITF: ILMN_2304186; MYCN: ILMN_1653761; NFE2L2: ILMN_1790909; TFE3:
ILMN_1764826; TFEB: ILMN_1733616; SDHA: ILMN_1744210. Real-time RT-PCR
was performed as described previously with at least three biological replicates and
two technical replicates.66 Data were normalized against neuroblastoma house-
keeping genes SDHA and HPRT69 and set in relation to negative control. The
following specific primer pairs were used: ABL1 (forward: 5′-TTGACCAAGCCTCT
ACAGGG-3′, reverse: 5′-AGACCCGGAGCTTTTCACCT-3′), ATG3 (forward: 5′-GA
CCCCGGTCCTCAAGGA A-3′, reverse: 5′-TGTAGCCCATTGCCATGTTGG-3′),
ATG16L2 (forward: 5′-TGGACAAGTTCTCAAAGAAGCTG-3′, reverse: 5′-CCTAGT
GCGACCAGTGAT-3′), HDAC6 (forward: 5′-CAAGGAACACAGTTCACCTTCG-3′,
reverse: 5′-GTTCCAAGGCACATTGATGGTA-3′), HDAC10 (Primer #1: forward:
5′-CTCACTGGAGCTGTGCAAAA-3′, reverse: 5′-GATCCTGTGTAGCCCGTGTT-3′;
Primer #2: forward: 5′-ATCTCTTTGAGGATGACCCCAG-3′, reverse: 5′-ACTGCGT
CTGCATCTGACTCTC-3′; Primer #3: forward: 5′-CAGTTCGACGCCATCTACTT
C-3′, reverse: 5′-CAAGCCCATTTTGCACAGCTC-3′), HPRT (hypoxanthine phos-
phoribosyltransferase 1, forward: 5′-TGACACTGGCAAAACAATGCA-3′ reverse:
5′-GGTCCTTTTCACCAGCAAGCT-3′), MAP1LC3A (forward: 5′-AACATGAGCGAG
TTGGTCAAG-3′, reverse: 5′-GCTCGTAGATGTCCGCGAT-3′), MAPT (forward:
5′-GATTGGGTCCCTGGACAATA-3′, reverse: 5′-GTGGTCTGTCTTGGCTTTGG-3′),
NPC1 (forward: 5′-GCACCTTTTACCATCACTCCTG-3′, reverse: 5′-GGCCACAGAC
AATAGAGCAGT-3′), PIM2 (forward: 5′-TTGACCAAGCCTCTACAGGG-3′, reverse:
5′-CCACCTGGAGTCGATCTGTGA-3′), RAB24 (forward: 5′-TACGTGGGCAAGAC
TAGCCT-3′, reverse: 5′-GCCCCGATGGTGTTCTGATAAG-3′), SDHA (succinate
dehydrogenase complex, subunit A, forward: 5′-TGGGAACAAGAGGGCATCTG-3′,
reverse: 5′-CCACCACTGCATCAAATTCATG-3′) and ULK1 (Qiagen: QT00009884).
In vitro HSP70 deacetylation activity assay. The inhibitory activity of
bufexamac towards HDAC-mediated HSP70-peptide deacetylation was measured
according to the HDAC activity protocol.66,70 Briefly, an equal amount of BE(2)-C
cell lysate (6.5 μg) per sample was used as an enzyme source. The substrate
SQRQATK(Ac) (final concentration: 10 μM) was synthesized and conjugated with
AMC by Peps4LS (Heidelberg, Germany). The HDAC reaction was performed at
37 °C for 30 min before adding the developer reagent. The free AMC was detected
after 30 min of incubation time with excitation of 380 nm and emission 460 nm at
kinetic mode for 10 min.
Web-based gene expression analysis. R2 (R2: microarray analysis and
visualization platform; http://r2.amc.nl) was used for principal component analysis
(PCA) and to investigate expression of the TOP10 regulated autophagy-related
genes in a publically available mixed cohort of primary neuroblastoma patients
(Academic Medical Center (AMC) - Versteeg; Gene Expression Omnibus (GEO)
database accession no. GSE16476, chiptype u133p2) and neuroblastoma
monolayer cell lines (Academic Medical Center (AMC) - Versteeg; Gene Expression
Omnibus (GEO) database accession no. GSE28019, chiptype u133p2). The subset
of tumors and cell lines with MYCN amplification was used and the following
probesets were applied: ABL1: 202123_s_at; ATG16L2: 229389_at; ATG3:
221492_s_at; FOXO3: 224891_at; HDAC6: 206846_s_at; HDAC10: 226672_s_at;
HIF-1 A: 200989_at; HPRT: 202854_at; MAP1LC3A: 227219_x_at; MAPT:
225379_at; MITF: 226066_at; MYCN: 209757_s_at; NFE2L2: 201146_at; NPC1:
202679_at; PIM2: 204269_at; RAB24: 225251_at; SDHA: 201093_x_at; TFE3:
212457_at; TFEB: 50221_at; ULK1: 209333_at. Patient characteristics were
published previously.71 A representative picture for an HE-stained patient sample
(#itcc0056) is provided in Supplementary Figure S1d, indicating a high tumor-to-
stroma ratio (source: http://r2.amc.nl). Comparison of gene expression level
between tissue and cell line samples from the R2 neuroblastoma mixed database
was performed on data normalized to SDHA expression using a two-tailed unpaired
t-test using the statistical software R (R version 3.2.1, 2015; The R Foundation for
Statistical Computing). Gene expression was normalized to the neuroblastoma
housekeeping gene, SDHA, to maintain comparability with our real-time PCR
analysis (see above).
Statistical analysis. Principal component analysis (PCA) was used to visually
assess similarities and differences between samples and determine whether
samples can be grouped. The analysis was performed by applying a singular value
decomposition to the mean-centered gene expression values of the 1000 genes
showing highest variability as determined by fitting a linear model using the limma
package in R.72,73
In order to identify pathways that are differentially regulated between 2D and 3D
(static and bioreactor system) cell cultures, we applied a globaltest.34 This test
evaluates Gene Ontology (GO) terms (http://www.geneontology.org/) of the
‘Biological Process’ ontology.
In addition, we sorted the regulated genes with the GO term ‘autophagy’
(GO:006914) by component P-value to identify the TOP10 genes, meaning the ten
genes with lowest component P-value. These component P-values reflect the
contribution of each gene to the global test statistic and serve here as an explorative
tool to rank genes. They cannot be used to control a type one error rate or make
inferential decisions and therefore we leave them unadjusted for multiplicity. These
calculations were performed using the Bioconductor Version 2.10 released 2 April
2012.74
Heatmaps showing gene expression were generated using the package pheatmap
in R (Raivo Kolde (2015). pheatmap: Pretty Heatmaps. R package version 1.0.7.
http://CRAN.R-project.org/package= pheatmap). Dendrograms shown for the
heatmaps reflect the result of a hierarchical clustering analysis, which was performed
using Ward’s method, with an algorithm that preserves Ward’s criterion.
IC50/EC50 values were calculated with GraphPad Prism version 5.00 for Windows,
GraphPad Software, San Diego California USA, www.graphpad.com. Each
experiment was repeated at least thrice. For statistical analysis of cell culture
experiments, a two-tailed t-test of significance was performed to compare
treatments using GraphPad Prism. For real-time PCR analysis, all samples
were normalized to 2D samples (= 1.0) and a one-sample t-test was used to test
whether means of 3D samples or tissue samples, respectively, are significantly
different from a hypothetical value (1.0), using GraphPad Prism version 3.0a. P-
values less than 0.05 were considered significant (***Po0.001; **0.001⩽Po0.01;
*0.01⩽Po0.05).
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